Sign in

    Marc Stapley

    Chief Executive Officer at Veracyte Inc
    Board
    Since June 1, 2021
    Age
    54 years
    Education
    Holds a B.Sc. (Honors) in Mathematics from The University of Reading (England).
    Tenure
    Joined VCYT as Chief Executive Officer on June 1, 2021 and as a board member on June 8, 2021.

    Also at Veracyte Inc

    AM
    Annie McGuire
    General Counsel and Chief People Officer
    JL
    John Leite
    Chief Commercial Officer, CLIA
    PF
    Phillip Febbo
    Chief Scientific Officer and Chief Medical Officer

    About

    Marc Stapley holds a B.Sc. (Honors) in Mathematics from The University of Reading (England), highlighting his strong academic background.

    He has built a notable career in life sciences and healthcare, holding leadership roles at major companies such as Pfizer, Illumina, and Helix OpCo, LLC, which underscores his expertise in finance and executive management.

    At VCYT, he joined as Chief Executive Officer on June 1, 2021 and became a member of the Board of Directors on June 8, 2021, reflecting his pivotal role in the company’s strategic direction.

    His extensive experience in both operational and financial leadership, combined with his governance roles at other industry companies, provides a well-rounded foundation for his ongoing contributions at VCYT.

    $VCYT Performance Under Marc Stapley

    Past Roles

    OrganizationRoleDate RangeDetails
    Helix OpCo, LLC Chief Executive Officer April 2019 - May 2021 Served as CEO before joining VCYT
    Illumina, Inc. Chief Financial Officer January 2012 - January 2017
    Illumina, Inc. Chief Administrative Officer December 2015 - October 2017
    Illumina, Inc. Executive Vice President October 2017 - January 2019
    Pfizer Inc. Senior Vice President, Finance 2009 - 2012

    External Roles

    OrganizationRoleDate RangeDetails
    Glaukos Corporation Board Member Since 2014 Active board membership
    Helix Board Member Since 2015 Active board membership

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Salary$650,000 AnnuallyFixed annual base salary
    Restricted Stock Units78,044 RSUs; $1,851,984 Fair Value Vesting: 1/4 on 1-year anniversary, then 1/16th quarterlyVesting acceleration upon specified events
    Option Awards128,869 options; $1,927,416 Fair Value; $23.73/share Vesting: 1/4 on 1-year anniversary, then 1/48th monthlySubject to acceleration upon certain events
    All Other Compensation$3,000 AnnuallyAdditional cash component

    Performance Compensation

    Data from  FY 2023

    Annual Cash Incentive Plan

    MetricWeightingThresholdTargetMaximumActualAchievement
    Total Revenue60% $325M $340M $370M $358.5M 131% of target payout
    Ending Cash Balance40% $150M $160M $200M $216.4M 150% of target payout
    • Corporate Multiplier: 138.5%
    • Target Bonus: $650,000
    • Earned Bonus: $900,250

    Performance Stock Units (PSUs)

    MetricValue
    Grant DateMarch 6, 2023
    Grant Date Fair Value$1,851,984
    Grant Date Stock Price$23.73 per share
    Threshold58,533 shares
    Target78,044 shares
    Maximum117,066 shares
    Vesting Schedule40% vests in 2025 (performance period ending Dec 31, 2024) and 60% vests in 2026 (performance period ending Dec 31, 2025)
    Vesting Range75% to 150% based on achievement of performance metrics
    Max Outcome Value$3,220,486 if performance reaches 150% target
    • Conditions: Continued service and achievement of performance metrics are required; vesting may accelerate upon specified events